Vertex Pharmaceuticals is making waves with its new pain treatment, Journavx, which is experiencing a prescription growth ...

William Blair just gave Vertex Pharmaceuticals a shiny bump in its 2025 earnings forecast, increasing EPS to $16.20 from ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we ...

Proceeds from Vertex’s (ASX:VTX) $11m capital raising will support the start of underground mining this year at its Hill End gold project.

Solar financing platform Metafin has raised $10 million in a Series A funding round led by Vertex Ventures Southeast Asia and India. Subscribe now to enjoy unlimited access at just $59. Premium ...

The market expects Vertex Pharmaceuticals (VRTX) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known ...

With a market cap of $122.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) operates as a global biotechnology company that develops and commercializes therapies for treating cystic fibrosis (CF).

She reiterated her buy recommendation on Vertex stock, and kept her $583-per-share price target intact. According to reports, Merle's update was based on surveys with medical professionals ...

Eli Lilly should be appealing to both growth and income investors. Vertex has a virtual monopoly in treating CF and multiple growth drivers. When the stock market is highly volatile, many ...